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Abstract
Background: Activation of spinal cord glial cells such as microglia and astrocytes has been shown to regulate
chronic opioid-induced antinociceptive tolerance and hyperalgesia, due to spinal up-regulation of the
proinflammatory cytokines such as interleukin-1 beta (IL-1b). Matrix metalloprotease-9 (MMP-9) has been implicated
in IL-1b activation in neuropathic pain. However, it is unclear whether acute opioid treatment can activate glial
cells in the peripheral nervous system. We examined acute morphine-induced activation of satellite glial cells
(SGCs) and up-regulation of IL-1b in dorsal root ganglia (DRGs), and further investigated the involvement of MMP-9
in these opioid-induced peripheral changes.
Results: Subcutaneous morphine injection (10 mg/kg) induced robust peripheral glial responses, as evidenced by
increased GFAP expression in DRGs but not in spinal cords. The acute morphine-induced GFAP expression is
transient, peaking at 2 h and declining after 3 h. Acute morphine treatment also increased IL-1b immunoreactivity
in SGCs and IL-1b activation in DRGs. MMP-9 and GFAP are expressed in DRG neurons and SGCs, respectively.
Confocal analysis revealed a close proximity of MMP-9 and GFAP immunostaining. Importantly, morphine-induced
DRG up-regulation of GFAP expression and IL-1b activation was abolished after Mmp9 deletion or naloxone pre-
treatment. Finally, intrathecal injections of IL-1b-selective siRNA not only reduced DRG IL-1b expression but also
prolonged acute morphine-induced analgesia.
Conclusions: Acute morphine induces opioid receptors- and MMP-9-dependent up-regulation of GFAP expression
and IL-1b activation in SGCs of DRGs. MMP-9 could mask and shorten morphine analgesia via peripheral neuron-
glial interactions. Targeting peripheral glial activation might prolong acute opioid analgesia.
Background
Mounting evidence indicates that activation of spinal
cord glial cells such as microglia and astrocytes plays a
crucial role in the pathogenesis of chronic pain [1-7]. In
particular, chronic opioid exposure induces profound
changes in spinal cord microglia and astrocytes [8-10].
Upon activation spinal glial cells produce multiple proin-
flammatory cytokines such as TNF-a,I L - 1 b,a n dI L - 6t o
antagonize morphine analgesia and promote morphine
tolerance [11-14], via sensitization of spinal cord dorsal
horn neurons [15-17]. For example, IL-1b has been
shown to counteract opioid-induced analgesia following
both chronic and acute administration of morphine [18].
While intrathecal injection of the inteurleukin-1 receptor
(IL-1R) antagonist potentiates acute morphine analgesia
[11], intrathecal administration of IL-1b induces heat
hyperalgesia [15]. Of interest genetic polymorphism of
IL-1R antagonist has been implicated in the variation in
postoperative morphine consumption [19].
Our previous study has shown that matrix metallopro-
teinase 9 (MMP-9) plays an important role in neuroin-
flammation and neuropathic pain development in part
through the activation (active cleavage) of IL-1b [20].
MMP-9 has also been shown to regulate the phenotype
and proliferation of peripheral [21] and central [20] glial
cells. In a parallel study, we also showed that acute mor-
phine induced a rapid up-regulation of MMP-9 in primary
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any medium, provided the original work is properly cited.sensory neurons in the dorsal root ganglia (DRGs), mask-
ing morphine-induced analgesia (Liu et al., unpublished
data). However, the molecular and cellular mechanisms by
which MMP-9 suppresses/shortens acute opioid analgesia
are unclear.
Satellite glial cells (SGCs) are peripheral glial cells and
form a continuous layer around primary sensory neurons
within DRGs and trigeminal ganglia (TGs). SGCs have
been shown to regulate neuronal homeostasis and neuro-
transmission in DRGs and TGs [22]. Increasing evidence
suggests that SGCs exhibit marked morphological and
biochemical changes following peripheral nerve injury
and inflammation [23-27]. Peripheral inflammation sup-
presses inward rectifying potassium currents and
increases IL-1b expression in SGCs of TG, leading to
neuronal firing and trigeminal pain [28,29]. Chemokine
signaling in DRG SGCs and neurons was shown to regu-
late chronic opioid-induced hyperalgesia [30]. However,
it is unclear whether and how SGCs are activated in
DRGs following acute opioid treatment. Our data
demonstrated that a single subcutaneous morphine injec-
tion could induce MMP-9 and opioid receptors-depen-
dent activation of SGCs and IL-1b in DRGs, highlighting
the importance of peripheral neuronal-satellite glial inter-
actions for the control of acute opioid analgesia.
Results
Subcutaneous morphine induces GFAP expression in
DRGs but not in spinal cords
The first question we addressed is whether acute mor-
phine-induced acute analgesia is associated with peripheral
glial responses in DRGs. We used GFAP as a marker for
SGCs and performed immunohistochemistry to examine
GFAP expression in DRGs, 2 h after saline and morphine
injection when morphine analgesia declines. In DRGs of
saline-treated control mice, only weak GFAP staining was
observed (Figure 1A). Strikingly, the intensity of GFAP
staining was markedly increased in DRGs of morphine-
treated mice (Figure 1B).
Next, we performed qPCR analysis to quantify the
GFAP mRNA levels in DRGs and spinal cords at different
times of morphine injection. Acute morphine increased
GFAP mRNA expression in DRGs [F(3,12) = 30.9, P <
0.0001, One-Way ANOVA], which peaked at 2 h (4.5
fold of control, P < 0.05, n = 4) and declined but still
remained elevated at 3 h (2.6 fold of control, P < 0.05,
n = 4) (Figure 2A). In contrast, acute morphine did not
change GFAP mRNA expression in spinal cord dorsal
horns at all the time points we examined (F(3,12) = 0.51,
P = 0.682, One-Way ANOVA] (Figure 2B). Thus, it
appears that acute morphine only causes reaction of per-
ipheral glia (SGCs) but not of central glia, since GFAP is
a hallmark for astrocytes in the CNS.
MMP-9 is required for subcutaneous morphine-induced
GFAP expression in DRG SGCs
GFAP-positive SGCs were found to form ring-like stain-
ing around 5.5% DRG neurons of saline-treated mice
(Figure 3A, B). This percentage increased to 17.1 at 2 h
after morphine injection (Figure 3A, B; P < 0.05, n = 6).
To determine the contribution of MMP-9 to morphine-
elicited SGC reaction, we examined GFAP expression in
Mmp9 null mice (Mmp9
-/-). Compared to wild-type con-
trol mice, morphine-induced increase in ring-like stain-
ing of GFAP was abolished in Mmp9
-/- mice, and only
7.6% DRG neurons showed GFAP-ring (Figure 3A, B,
P <0.05, n = 6). Furthermore, qPCR analysis revealed that
morphine-induced DRG increase in GFAP mRNA
expression was also abrogated in Mmp9
-/- mice com-
pared to that of the wild-type mice (Figure 3C; 0.9 fold of
vehicle, P <0.05, n = 4). However, the basal expression
levels of GFAP mRNA in the wild-type and Mmp9
-/-
mice were very similar (P = 0.2468, Mann-Whitney test,
n = 4). Together, these data suggest that MMP-9 is
essential for GFAP up-regulation in DRG-SGCs following
acute morphine treatment.
In a parallel study, we demonstrated MMP-9 up-regu-
lation in DRG neurons after acute morphine treatment
(Liu et al., unpublished data). MMP-9 could be secreted
to extracellular space to trigger the reaction of sur-
rounding SGCs via neuronal-glial interaction. Double
staining of MMP-9 and GFAP and confocal microscopy
examination revealed that MMP-9 and GFAP-labeled
structures were in very close proximity but not over-
lapped (Figure 3D), providing a structural base for
MMP-9-initiated neuronal-glial interaction in DRGs.
Subcutaneous morphine induces IL-1b activation in DRG
SGCs via MMP-9
Chronic morphine but not acute morphine was shown
to increase IL-1b levels in the spinal cord [11]. We set
o u tt ot e s ti fa c u t em o r p h i n ew o u l di n d u c eI L - 1 b
expression and activation in DRGs. Low level of IL-1b
expression was observed in DRGs of saline-treated wild-
type animals: only 5.4% DRG neurons were surrounded
by IL-1b-expressing staining in the control animals.
However, this percentage increased to 22.7 in mor-
phine-treated wild-type mice (Figure 4A, B; P < 0.05,
n = 6). Notably, this increase was abrogated in Mmp9
-/-
mice, and only 7.4% DRG neurons were surrounded by
IL-1b-expressing satellite cells (Figure 4A, B; P < 0.05,
n = 6). However, acute morphine did not alter the
expression of the IL-1b mRNA (Figure 4C).
Next, we conducted Western blot analysis to check
the activation of IL-1b in DRGs after morphine treat-
ment. Morphine produced no significant change of the
28 kDa band of IL-1b, the non-mature form of IL-1b
Berta et al. Molecular Pain 2012, 8:18
http://www.molecularpain.com/content/8/1/18
Page 2 of 13(Figure 4D). In contrast, morphine induced a significant
increase of the 17 kDa band of IL-1b, the active form of
IL-1b, in DRGs of wild-type mice (Figure 4D, E, 1.4 fold
of control, P < 0.05, n = 4). Notably, this increase of the
active form of IL-1b was completely abolished in
Mmp9
-/- mice (Figure 4D, E).
To determine the cellular localization of IL-1b in
DRGs, we carried out triple staining for GFAP, IL-1b,
and DAPI (nuclear marker). We found a clear co-locali-
zation of GFAP and IL1b in cytoplasm of SGCs of mor-
phine-treated mice (Figure 5). Together, our results
suggest that MMP-9 is required for the morphine-
induced IL-1b activation in SGCs.
Intrathecal opioids increase GFAP expression and IL-1b
activation in DRGs but not in spinal cords
To determine whether morphine would directly act on
DRG cells to produce the observed effects, we intrathe-
cally injected morphine or remifentanil, a potent fast-act-
ing synthetic opioid. Single intrathecal injection of
morphine (10 nmol) and remifentanil (1 noml) elicited
significant increases in GFAP levels [(F(2,9) = 13.1, P =
0.002, One-Way ANOVA] and IL1b (17 kDa) levels [(F
(2,9) = 8.6, P = 0.008, One-Way ANOVA] in DRGs (Fig-
ure 6A). In contrast, intrathecal morphine and remifenta-
nil failed to induce GFAP and IL-1b (17 kDa) expression
in spinal cord dorsal horns (Figure 6B). These results
i n d i c a t et h a tD R G sa r ep r i m a r yt a r g e tf o ra c u t eo p i o i d -
induced GFAP expression and IL-1b activation.
Intrathecal injection of IL-1b-targeting siRNA prolongs
morphine analgesia
IL-1b antagonist has been shown to potentiate acute
morphine analgesia and reduce morphine tolerance
[11,31]. We further evaluated the role of IL-1b in acute
opioid analgesia using a different strategy to knock
down DRG-IL-1b expression via intrathecal route. Com-
pared to non-targeting control siRNA, IL-1b siRNA
treatment significantly increased tail-flick latency at 2 h
(Figure 7A, P < 0.05, Bonferroni post hoc test, n = 6)
but not at 1 h (Figure 7A, P > 0.05). It is suggested that
IL-1b siRNA treatment could prolong opioid analgesia.
Figure 1 Subcutaneous morphine increases GFAP immunoreactivity in DRG SGCs. (A, B) GFAP immunoreactivity in DRGs from saline (A) or
morphine (B, 10 mg/kg, s.c.) treated mice at 2 h after the injections. Left panels are images with high contrast showing all DRG cells in an optic
field. Middle and right panels are low and high magnification images of GFAP staining. Note there is a marked increase in GFAP staining after
acute morphine treatment. Scales, 50 μm.
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siRNA on IL-1b expression in DRG and spinal cord tis-
sues collected 2 h after morphine injection. Notably,
morphine-induced IL-1b expression in DRGs was
reduced by 40% after intrathecal IL-1b siRNA treatment,
compared with control siRNA (Figure 7B, P <0.05,
Mann-Whitney test, n = 6). However, the same IL-1b
siRNA treatment (i.t.) did not produce significant reduc-
tion of IL-1b expression in spinal cord dorsal horns at
2 h after morphine injection (Figure 7C, P > 0.05,
Mann-Whitney test, n = 6). One possible explanation
for the differential knockdown of DRG vs. spinal cord
IL-1b by intrathecal siRNA treatment is that DRG IL-1b
is inducible after morphine treatment, therefore, more
sensitive to siRNA treatment, as shown in our previous
study [32,33]. In contrast, knockdown of constitutive IL-
1b expression in the spinal cord may require high doses
and additional injections of siRNA. Since the IL-1b
siRNA treatment only reduced DRG IL-1b,w h i c hi s
expressed in SGCs, we hypothesize that IL-1b expressed
by peripheral DRG glia (SGCs) plays a role in masking/
diminishing morphine-induced analgesia.
Morphine induces GFAP up-regulation and IL-1b
activation in DRG SGCs via opioid receptors
Morphine could induce SGC activation via opioid recep-
tors-dependent and independent mechanisms, such as
activation of toll-like receptors [34]. To address this
issue, we investigated the effects of the opioid receptor
antagonist naloxone on the morphine-induced GFAP
expression and IL-1b activation. Pre-treatment of nalox-
one (10 mg/kg, s.c.), 10 min prior to the morphine injec-
tion, completely blocked the morphine-evoked GFAP
mRNA expression (Figure 8A, P <0.05, One-Way
ANOVA) and IL-1b activation (Figure 8B, C, P <0.05,
One-Way ANOVA) in DRGs.
Discussion
In the present study, together with another study in an
accompanying paper (Liu et al., unpublished data), we
provided several lines of evidence that support an
important role of DRG satellite glial cells (SGCs) in
masking and shortening opioid analgesia, via neuron-
glial interactions in DRGs (Figure 9). (1) Subcutaneous
or intrathecal opioid (morphine and remifentanil)
induced rapid and transient MMP-9 expression (1-3 h)
in DRG neurons but not in the spinal cord (Liu et al.,
unpublished data). (2) Subcutaneous or intrathecal
opioid induced GFAP expression (at 2 h) in DRG SGCs
but not in the spinal cord (Figures 1, 2, and 6). (3) Sub-
cutaneous or intrathecal opioid induced IL-1b activation
(at 2 h) in DRG SGCs but not in spinal cords (Figures 4
and 6). (4) The morphine-induced SGC activation
(GFAP expression and IL-1b activation) in DRGs was
abolished after Mmp9 deletion and naloxone pre-treat-
ment (Figures 3, 4, and 8). (5) Acute morphine-induced
analgesia was enhanced and prolonged after Mmp9 dele-
tion or by MMP-9 inhibition via intrathecal route (Liu
et al., unpublished data). (6) Intrathecal treatment of IL-
1b siRNA (using a mild protocol with 2 injections) pro-
duced IL-1b knockdown in DRGs (but not in spinal
cords) and also prolonged morphine-elicited analgesia
(Figure 7). Based on these findings, we postulate that
neuronal MMP-9 expression and subsequent MMP-9
release following acute morphine treatment triggers the
activation of SGCs (IL-1b activation), diminishing the
analgesic efficacy of opioid (Figure 9).
Figure 2 Subcutaneous morphine induces GFAP mRNA
expression in DRGs but not in spinal cords. (A, B) Real-time RT-
PCR showing the time course of GFAP expression in lumbar DRGs
(A) and spinal cord dorsal horns (B) after subcutaneous morphine
injection (10 mg/kg, s.c.). Note that acute morphine only increases
GFAP mRNA expression in DRGs but not in spinal cord dorsal horns.
The data are expressed as fold of naïve controls. *P < 0.05, vs.
control, ANOVA followed by Bonferroni post hoc test, n = 4 mice.
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Page 4 of 13Figure 3 MMP-9 is required for subcutaneous morphine-induced GFAP expression in SGCs of DRGs. (A) Left panels: DAPI nuclei staining
of all cells in DRG sections of saline (up panel) and morphine (2 h, middle and low panels) treated wild-type (WT) mice and morphine-treated
Mmp9 knockout mice (Mmp9
-/-, low panel). Stars and arrows indicate neurons (no staining) and SGCs, respectively. Note that Mmp9 knockout
mice show no changes in DRG cell numbers. Right panels: Immunohistochemistry showing GFAP-labeled SGCs in DAPI-stained DRG sections.
Scale, 50 μm. (B) Percentage of DRG neurons with GFAP-labeled ring. Note that morphine-induced GFAP increase at 2 h is abrogated in Mmp9
knockout mice. *P < 0.05, compared to WT control;
#P < 0.05 compared to morphine/WT, ANOVA followed by Bonferroni post hoc test, n = 6
mice. (C) GFAP mRNA expression in DRGs revealed by real time RT-PCR analysis. Note that morphine-induced GFAP mRNA expression (2 h) in
WT mice is abolished in Mmp9 knockout mice. *P < 0.05, compared to WT control;
#P < 0.05 compared to morphine/WT; ANOVA followed by
Bonferroni post hoc test, n = 4. (D) Confocal images showing doubles staining of MMP-9 and GFAP in DRG sections of WT mice 2 h after
morphine treatment. Square 1 and 2 are enlarged in middle and right panels. Note there is close proximity but not overlap of MMP-9 and GFAP
staining. Scales, 10 μm.
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Page 5 of 13Figure 4 MMP-9 is required for subcutaneous morphine-induced IL-1b activation in DRGs. (A) DAPI nuclei staining (left panels) and IL-1b
immunostaining (right panels) in DRG sections of saline (upper panels) and morphine (middle panels) treated wild-type (WT) mice and
morphine-treated Mmp9 knockout mice (Mmp9
-/-, lower panels). Scale, 50 μm. (B) Percentage of DRG neurons with IL-1b-labeled ring. Note that
morphine-induced IL-1b increase is abrogated in the Mmp9 knockout mice. *P < 0.05, compared to WT control;
# P < 0.05 compared to
morphine/WT, ANOVA followed by Bonferroni post hoc test, n = 6 mice. (C) Real-time RT-PCR analysis showing IL-1b mRNA expression in DRGs
of saline and morphine treated mice (10 mg/kg, s.c., 2 h). P > 0.05, Mann-Whitney test, n = 4. (D) Western blotting showing non-mature (28
kDa) and mature/active (17 kDa) bands of IL-1b in DRGs of WT and Mmp9
-/- mice with or without morphine treatment (10 mg/kg, s.c., 2 h). Note
that the 28 kDa bands were unaltered after morphine treatment. (E) Intensity of the active IL-1b (17 kDa) bands. Note that morphine-induced
activation of IL-1b is abrogated in Mmp9
-/-mice. *P <0.05, compared to WT control;
#P <0.05 compared to morphine/WT, ANOVA followed by
Bonferroni post hoc test, n = 4 mice.
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Page 6 of 13Figure 5 Co-localization of GFAP and IL-1b in SGCs of DRGs. (A) Triple staining showing co-localization of GFAP (green), IL-1b (red), and
DAPI (blue) in DRG-SGCs of morphine (2 h)-treated mice. Star and arrows indicate neurons and satellite glia, respectively. (B) High magnification
images of boxes in A. Scales, 20 μm.
Figure 6 Intrathecal injection of morphine and remifentanil increases GFAP expression and IL-1b activation in DRGs but not in spinal
cords. (A) Western blotting showing the expression of GFAP and IL-1b (17 kDa cleaved form) in DRGs after intrathecal injection of morphine (10
nmol, 2 h) and remifentanil (1 nmol, 2 h). (B) Quantification of GFAP and IL1b (17 kDa) bands in DRGs. *P < 0.05, compared to saline control;
ANOVA followed by Bonferroni post hoc test, n = 4 mice. (C) Western blotting showing the expression of GFAP and IL-1b (17 kDa) in spinal
cord dorsal horns after intrathecal injection of morphine (10 nmol, 2 h) and remifentanil (1 nmol, 2 h). (D) Quantification of GFAP and IL-1b
bands in spinal cord dorsal horns. Note there is no change in spinal GFAP expression and IL-1b activation after morphine treatment. *P < 0.05,
compared to saline control; ANOVA followed by Bonferroni post hoc test, n = 4 mice. CTRL, vehicle control; MORPH, morphine; REMIF,
remifentanil.
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showing that acute morphine could induce satellite glial
activation in DRGs. We found significant increases in both
mRNA and protein levels of the satellite glial marker
GFAP after a single subcutaneous injection of morphine
(Figures 1 and 2), indicating a peripheral glial reaction by
acute morphine. In sharp contrast, previous studies have
focused on chronic morphine treatment and central glial
activation. For example, chronic morphine induced up-
regulation of the microglial markers CD11b and IBA1 and
the astrocyte marker GFAP in the spinal cord
[8,9,12,35,36]. In particular, chronic morphine activates
p38 MAP kinase in spinal cord microglia to promote mor-
phine tolerance [10,36-38]. However, we failed to detect
increases in the expression of spinal glial markers such as
the astrocyte marker GFAP (Figures 2 and 6) and the
microglial marker IBA-1 (data not shown) after single sub-
cutaneous and intrathecal injections of morphine, suggest-
ing that acute morphine primarily induces peripheral glial
responses in DRGs.
SGCs in the DRG are tightly associated with sensory
neurons via gap junction; and gap junction communication
between SGCs and neurons is greatly enhanced in persis-
tent pain conditions [39,40]. Neuron-glial interactions in
Figure 7 Intrathecal injections of IL-1b siRNA prolong morphine analgesia and reduce IL-1b expression in DRGs. (A) Acute morphine-
induced analgesia is prolonged after intrathecal injections of IL-1b siRNA (3 μg, 24 and 2 h prior to morphine injection). Morphine analgesia was
tested at 1 h and 2 h after the morphine injection (10 mg/kg, s.c.). *P <0.05, compared to non-targeting control (CTRL) siRNA, Two-Way ANOVA
followed by Bonferroni post hoc test, n = 6 mice. (B, C) Western blotting analysis showing IL-1b expression (17 kDa) in DRGs (B) and spinal cord
dorsal horns (C) after intrathecal injections of IL-1b siRNA (siRNA) or control siRNA. *P <0.05, compared to control, Mann-Whitney test, n = 6 mice.
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injury, chronic inflammation, and DRG compression,
SGCs exhibit robust up-regulation of GFAP [43-45]. Nerve
injury-induced SGC reaction depends on neuronal activity
and local inflammation [23,46]. Our data showed that mor-
phine-induced GFAP induction in SGCs required MMP-9
(Figure 3). As an extracellular matrix protein, MMP-9
could be released from DRG neurons following morphine
stimulation and retain in extracellular space between neu-
rons and satellite cells. MMP-9 may cleave extracellular
matrix proteins to induce satellite glial reaction and GFAP
up-regulation (Figure 8). Of note MMP-9 immunostaining
in neurons had very close proximity to GFAP immunos-
taining in SGCs (Figure 3D). MMP-9 has been shown to
regulate phenotypic remodeling and proliferation of per-
ipheral glial cells such as Schwann cells via signaling of
IGF-1, ErbB receptors, and ERK [21].
In particular, our data demonstrated that MMP-9
could drive IL-1b activation after acute morphine. Acute
morphine induced IL-1b activation in the DRG but not
Figure 8 Naloxone blocks subcutaneous morphine-induced GFAP expression and IL-1b activation in DRGs. (A) Real-time RT-PCR showing
GFAP mRNA expression in DRGs after subcutaneous morphine injection (10 mg/kg, 2 h) with or without naloxone pre-treatment (10 mg/kg, 15
min prior to the morphine injection). Note that morphine-induced GFAP expression is completely blocked by naloxone. The data are expressed
as fold of controls. *P < 0.05, vs. control, ANOVA followed by Bonferroni post hoc test, n = 4 mice. (B) Western blotting showing the expression
of active form of IL-1b (17 kDa) in DRGs after subcutaneous morphine with or without naloxone pre-treatment. (C) Intensity of IL-1b bands (17
kDa) in DRGs. Note that morphine-induced IL-1b activation is completely abolished by naloxone. *P < 0.05, compared to saline control, ANOVA
followed by Bonferroni post hoc test, n = 4. CTRL, control; VEH, vehicle; NAL, naloxone; MORPH, morphine.
Figure 9 Schematic of the working hypothesis illustrating how acute morphine induces SGCs activation in DRGs to mask morphine
analgesia. Acute morphine produces analgesia via μ opioid receptors (MOR). Acute morphine also induces MMP-9 up-regulation in DRG
neurons via MOR (Step-1). MMP-9 is secreted in extracellular space, inducing glial reaction and IL-1b cleavage (Step-2). The activated (cleaved) IL-
1b binds IL-1 receptors in neurons, in a paracrine or autocrine manner, and results in increasing excitability of nociceptive neurons to mask and
shorten morphine analgesia (Step-3).
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study failed to show IL-1b increase either in lumbar
spinal cord or in CSF after acute morphine injection
[11]. As previously reported [32,47,48], we observed IL-
1b expression by DRG SGCs. However, we should not
rule out the possibility that IL-1b could also be
expressed in neurons by testing different IL-1b antibo-
dies [32,49]. Primary sensory neurons particularly noci-
ceptors express IL-1 receptors, and notably, activation of
these receptors by IL-1b can rapidly activate nociceptors
to generate action potentials and elicit pain hypersensi-
tivity [50]. It appears that IL-1b increases the excitability
of sensory neurons via increasing sodium currents and
decreasing potassium currents [48,50,51]. Importantly,
intrathecal interleukin-1 receptor antagonist potentiates
both intrathecal and systemic morphine-induced analge-
sia [11,31]. Since IL-1b activation following acute mor-
p h i n ew a sp r i m a r i l yf o u n di nt h eD R G ,w ep o s t u l a t e
that intrathecal interleukin-1 receptor antagonist may
also enhance opioid analgesia by blocking IL-1b signal-
ing in DRGs. This notion is strongly supported by our
siRNA experiment, showing that morphine analgesia
was prolonged after IL-1b knockdown in DRGs by selec-
tive siRNA treatment (Figure 7).
Importantly, Mmp9 deletion resulted in a complete
loss of morphine-induced IL-1b activation in the DRG
(Figure 4). IL-1b is activated via cleavage from its pre-
cursor (≈ 31 kDa) and this activation is not only
mediated by caspase-1 (i.e. IL-1b converting enzyme)
but also mediated by other enzymes such as trypsin,
elastase, collagenase, and cathepsin G, and MMP-9
[52-54]. MMP-9 can cause direct activation of IL-1b
(generation of 17 kDa form) in a cell-free system [53].
Notably, caspase-1-deficient mice can still produce
bioactive IL-1b and mediate IL-1b-dependent reactions
under several pathological conditions [55]. Consistently,
nerve injury-induced DRG-IL-1b activation is abolished
in Mmp9
-/- mice, whereas intrathecal MMP-9 increases
IL-1b activation in DRGs [32]. However, we should not
exclude the possibility that at very high concentrations
MMP-9 may also cause IL-1b degradation and inactiva-
tion via direct cleavage of IL-1b at different sites [56].
In summary, opioids are still the most used analgesics
for the treatment of moderate to severe pain, despite
their well-known side effects. Increasing evidence shows
that spinal cord glial cells and proinflammatory cytokines
contribute to chronic opioid-induced antinociceptive tol-
erance and hyperalgesia via neuronal-glial interactions in
the spinal cord [12,13]. We have demonstrated that acute
morphine also induces peripheral satellite glial cell (SGC)
activation in the DRG, which is triggered by the protease
MMP-9. Morphine-induced MMP-9 up-regulation in
DRG neurons could mask morphine analgesia via neuro-
nal-glial interactions. Specifically, MMP-9 caused IL-1b
activation, leading to hyperexcitability of primary sensory
neurons to mask morphine analgesia (Figure 9). Thus,
opioids not only produce excitatory effects in the spinal
cord via postsynaptic [57,58] and presynaptic mechan-
isms [59], they could further elicit excitatory effects at
DRG level via MMP-9-triggered peripheral neuronalglial
interactions. Targeting peripheral neuronal-glial interac-
tions in DRGs may prolong the analgesic efficacy of
opioids.
Methods
Animals
All experiments were performed in accordance with the
guidelines of the National Institutes of Health and the
International Association for the Study of Pain. All ani-
mals were used under Harvard Medical School Animal
Care institutional guidelines. Adult male mice (25-35 g)
were used for behavioral and biochemical studies, includ-
ing CD1 mice (Charles River Laboratories, Wilmington,
MA), Mmp9 konckout (Mmp9
-/-) mice with FVB back-
ground, and FVB control wild-type mice. Mmp9 knockout
(KO) mice and FVB wild-type mice were obtained from
Jackson Laboratories (The Jackson Laboratory, Bar Har-
bor, ME). The KO mice are viable, fertile, and maintained
in FVB background for more than 5 generations. Mice
that are homozygous null for the Mmp9 gene were used
in this study. As previously described, they do not show
a n yd i f f e r e n c ei no v e r a l lw e ight and behavior compared
with wild-type mice [32]. Animals were housed in a 12 h
light/dark room with access to food and water ad libitum.
Drugs and administration
We purchased morphine sulphate and remifentanil from
Hospira (Lake Forest, IL) and naloxone form Sigma (St.
Louis, MO). Drugs were freshly prepared in saline and
administered subcutaneously in the lower back (10 mg/kg
for morphine and naloxone) or intrathecally (10 nmol for
morphine and 1 nmol for remifentanil). The IL-1b
(GCUCCGAGAUGAACAACAA) and control siRNAs
(GACUUCGCGGGACACAUGA) were purchased from
Dharmacon (Dharmacon, Inc., Chicago, IL). siRNA was
dissolved in RNase-free water at the concentration of 1
μg/μl as stock solution, and mixed with polyethyleneimine
(PEI, Fermentas Inc., Glen Burnie, MD), 10 min before
injection, to increase cell membrane penetration and
reduce the degradation. PEI was dissolved in 5% glucose,
and 1 μg of siRNA was mixed with 0.18 μl of PEI. siRNA
(3 μg) was intrathecally injected 24 and 2 h before the
morphine injection. Of note, agents with different chemi-
cal properties have been shown to affect DRG cells via
intrathecal route, including small molecules such as MAP
kinase and MMP-9 inhibitors [32,60] and large molecules
such as growth factors and peptides [61,62], as well as
antisense oligodeoxynucleotides [63,64] and siRNAs
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inhibit p38 activation in DRG neurons within half hour
[66]. Thus, intrathecal delivery of siRNA should affect
cells both in DRGs and spinal cords.
Behavioral test
All animals (n = 6 mice per group) were habituated to
testing environment for at least 2 days before baseline
testing. Morphine analgesia was evaluated by measuring
the tail-flick latencies in hot water [67]. Briefly, tail-flick
test was performed by gently holding the mouse
wrapped with a terry towel and kept tail exposed. Then
one third of the length of the tail was immersed into
the 52°C hot water, and the response latency was
defined as removal of the whole tail from the water. A
maximum cut-off value of 10 seconds was set to avoid
thermal injury.
Immunohistochemistry
Two hours after morphine or vehicle (saline) injection,
animals (n = 6 mice per group) were terminally anesthe-
tized with isoflurane and perfused through the ascending
aorta with PBS, followed by 4% paraformaldehyde with
1.5% picric acid in 0.16 M PB. After the perfusion, DRGs
(L4/L5) were removed and postfixed in the same fixative
overnight. DRG sections (12 μm) were cut in a cryostat
and processed for immunofluorescence. All the sections
were blocked with 10% goat serum, and incubated over
night at 4°C with the primary antibodies against GFAP
(mouse, 1:2000, Millipore, Billerica, MA), MMP-9 (1:1000,
rabbit, Millipore), or IL-1b (1:1000, rabbit, Millipore;
1:500, goat, R&D System, Minneapolis, MN) with 5% goat
serum. The sections were then incubated for 1 h at room
temperature with Cy3- or FITC-conjugated secondary
antibody (1:400, Jackson Immunolab, West Grove, PA)
with 1% goat serum. DAPI (4’,6-diamidino-2-phenylindole;
Sigma) staining was used to determine the cell nuclei. For
double immunofluorescence, sections were incubated with
a mixture of polyclonal and monoclonal primary antibo-
dies followed by a mixture of FITC- and CY3-congugated
secondary antibodies [68]. The stained sections were
examined under a Nikon fluorescence microscopy, and
images were captured with a CCD camera (SPOT, Diag-
nostic Instruments). To obtain high-resolution images,
confocal images were captured from some DRG section
with a Zeiss LSM 510 META upright confocal micro-
scope. All images were analyzed with NIH Image software
or Adobe Photoshop.
Western blot
Animals (n = 4-6 mice per group) were terminally
anesthetized with isoflurane at 1, 2, and 3 h after mor-
phine injection and transcardially perfused with PBS.
DRGs (L4/L5) and spinal cord segments (dorsal part of
L4-L5) were rapidly removed and homogenized in a
lysis buffer containing a cocktail of protease inhibitors
and phosphatase inhibitors [69]. The protein concentra-
tions were determined by BCA Protein Assay (Pierce
Biotechnology, Inc., Rockford, IL). Twenty micrograms
of proteins were loaded for each lane and separated on
SDS-PAGE gel (4-15%, Bio-Rad). After the transfer, the
blots were incubated overnight at 4°C with polyclonal
antibody against GFAP (mouse, 1:1000, Millipore) or IL-
1b (1:1000, rabbit, Millipore). For loading control, the
blots were probed with b-tubulin or GAPDH antibody
(mouse, respectively 1:2000 and 1:20000, Sigma).
Quantitative real-time PCR (qPCR)
Animals (n = 4 per group) were terminally anesthetized
with isoflurane at 1, 2, and 3 h after morphine injection.
DRGs (L4/L5) and spinal cord dorsal horn segments
(L4-L5) were rapidly dissected and total RNA from each
animal was isolated using RNeasy Plus Mini kit (Qiagen,
Valencia, CA). One microgram of RNA was reverse
transcribed (RT) using Omniscript reverse transcriptase
according to the protocol of the manufacturer (Qiagen).
The sequences for the forward and reverse primers of
GFAP and GAPDH are included in Table 1. SYBR-
green qPCR analyses were performed using the Opticon
real-time PCR Detection System (Bio-Rad, Hercules,
CA) as described previously [70]. Briefly, qPCR amplifi-
cation reactions contained RT products, 7.5 μlo f2 X
iQSYBR-green mix (Bio-Rad), 300 nM of forward and
reverse primers completed with nanopure water for a
final volume of 15 μl. The thermal cycling conditions
were: 3 min at 95°C for the polymerase activation, 45
cycles of 10 s at 95°C for denaturation, and 30 s at 60°C
for annealing and extension, followed by a DNA disso-
ciation curve for the determination of the amplicon spe-
cificity. Analyses were carried out in triplicates and
included the different primer efficiencies obtained by a
standard curve method.
Statistical analyses
All results are presented as means ± SEM. Differences
between means were tested for significance using Mann-
W h i t n e yt e s t ,1 - w a yo r2 - w a yA N O V Af o l l o w e db y
Table 1 Sequences of the primer sets for RT-PCR
Target Gene Forward Primers Reverse Primers Genbank No.
GFAP GAATCGCTGGAGGAGGAGAT GCCACTGCCTCGTATTGAGT NM010277
GAPDH TCCATGACAACTTTGGCATTG CAGTCTTCTGGGTGGCAGTGA XM001473623
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Page 11 of 13Bonferroni post hoc test. Significance was determined at
a level of P < 0.05.
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